Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

This multicenter, double blind trial evaluated the cardiovascular effects of ertugliflozin, an SGLT2 inhibitor, in patients with type 2 diabetes and atherosclerotic cardiovascular disease. A total of 8246 patients were randomized to receive 5 mg or 15 mg of ertugliflozin or placebo once daily. The primary outcome was major adverse cardiovascular events (MACE), with a noninferiority margin of 1.3. Results showed that ertugliflozin was noninferior to placebo for MACE (hazard ratio, 0.97; 95.6% CI, 0.85–1.11; P < 0.001). The key secondary outcome of cardiovascular death or hospitalization for heart failure did not reach statistical significance (hazard ratio, 0.88; 95.8% CI, 0.75–1.03; P = 0.11). Ertugliflozin demonstrated safety consistent with the SGLT2 inhibitor class, with increased genital mycotic infections but no significant difference in amputations or renal outcomes compared to placebo.

This multicenter, double blind trial evaluated the cardiovascular effects of ertugliflozin, an SGLT2 inhibitor, in patients with type 2 diabetes and atherosclerotic cardiovascular disease. A total of 8246 patients were randomized to receive 5 mg or 15 mg of ertugliflozin or placebo once daily. The primary outcome was major adverse cardiovascular events (MACE), with a noninferiority margin of 1.3. Results showed that ertugliflozin was noninferior to placebo for MACE (hazard ratio, 0.97; 95.6% CI, 0.85–1.11; P < 0.001). The key secondary outcome of cardiovascular death or hospitalization for heart failure did not reach statistical significance (hazard ratio, 0.88; 95.8% CI, 0.75–1.03; P = 0.11). Ertugliflozin demonstrated safety consistent with the SGLT2 inhibitor class, with increased genital mycotic infections but no significant difference in amputations or renal outcomes compared to placebo.